GxP validation for life sciences leaders who see further.
SWARE / RES_Q. The company's "See Further" brand image. From a Chelsea, Massachusetts startup named Boston Technology Research to a Salesforce validation partner - Sware works on the unglamorous machinery of regulated software.
Every time a life sciences company adopts a new piece of software - a lab system, a manufacturing tool, a cloud platform - a clock starts. Regulators such as the U.S. Food and Drug Administration require that the software be validated: documented, tested and proven to do what it claims, in accordance with GxP (Good Practice) rules and standards like 21 CFR Part 11. Done the old way, with printed protocols and wet-ink signatures, that work can stretch for weeks and pile up into what the industry quietly calls "validation debt."
Sware, a Boston-based software company, built its business on making that debt disappear. Its cloud-native platform, Res_Q, automates and connects the validation work that quality, IT and engineering teams have historically ground through by hand. A companion product, GxPNext, pushes that same rigor directly into the software development pipeline so that compliance is treated as code rather than a binder assembled after the fact.
The pitch is straightforward and, in a heavily regulated field, unusually contrarian: speed and compliance were never actually enemies - the tooling was just bad. Sware claims customers cut validation time by roughly 80% and lifetime computer system validation (CSV) costs by about 60%. Those numbers only land if you have watched a drug or device program stall because the software behind it wasn't cleared yet.
The company is not large - around 69 employees - but its reach outpaces its headcount. In 2025 Salesforce selected Sware to validate GxP compliance for its Life Sciences Cloud, and Box named the firm its Life Sciences Partner of the Year. For a company that most people outside pharma have never heard of, those are meaningful signals about where the expertise lives.
Every time a life sciences company adopts new technology, validation requirements add time and expenses. Automating these processes is the only way to eliminate this validation debt.Ellen Reilly, Chief Executive Officer, Sware
In life sciences, you cannot ship a therapy on the back of unvalidated software. That is not a preference - it is law. But the process most companies inherited is manual, document-heavy and slow, and it repeats every time a system is updated, migrated or replaced.
Sware attacks that in three ways. It automates the repetitive protocol and documentation work. It integrates validation across otherwise siloed systems - IT, manufacturing and lab - into a single source of truth. And it scales that approach as an organization grows, adds sites, or moves to the cloud.
The underlying asset is data. Sware's Res_Q Data Cloud is built on roughly a decade of real regulated validation knowledge, gathered first under the company's original name, Boston Technology Research. In an era of generic AI, that domain-specific corpus is the moat: the model matters less than the regulated work it was trained on.
What sets Sware apart is their deep domain understanding and expertise of relevant requirements and technology.Alvin Coleman, VP IT, G1 Therapeutics
Sware's platform spans five validation use cases: software, AI, plant and equipment, medical device / SaMD, and GxP for developers. Two products anchor it.
The intelligent, cloud-native GxP validation platform. Built on an open API architecture, it lets teams automate, integrate and scale validation across IT, manufacturing and lab systems in one place - covering GCP, GLP, GMP and AI validation, with the Res_Q Data Cloud beneath it.
Agentic validation software that lives inside the software development pipeline. It brings GxP compliance to the teams building life sciences applications - compliance as a rail along the whole track, not a gate at the very end.
End-to-end automated validation with dashboards for real-time compliance status, comprehensive audit support, industry-standard certifications and third-party reports - and integrations into existing quality tools.
Sware sells Res_Q and the GxP Suite as a B2B SaaS subscription to regulated life sciences organizations, wrapping services and audit support around the platform. A growing layer of platform partnerships - validating Salesforce Life Sciences Cloud, integrating with Box - extends its reach without adding proportional headcount.
The alternative to Sware, for most companies, is not a rival product - it is the status quo: traditional CSV consultancies and manual, document-based validation. That is the incumbent Sware is really competing against, alongside validation and quality software such as ValGenesis, Veeva Vault's quality modules, Kneat, MasterControl and TrackWise.
Sware's differentiation rests on three points. First, it is cloud-native and API-first, designed to connect 30+ industry applications rather than sit as an island. Second, its Res_Q Data Cloud is trained on a decade of actual regulated validation work, not generic data. Third, with GxPNext it reaches upstream to developers - a segment most validation tools ignore entirely.
There is also a credibility layer. A validation company that could not prove its own controls would be a locksmith with an unlocked door. Sware holds SOC 2 Type II and ISO 9001 certifications, and its selection by Salesforce to validate the Life Sciences Cloud functions as third-party endorsement of the approach.
The market backdrop favors this bet. The FDA's shift toward Computer Software Assurance (CSA) - a lighter, risk-based alternative to heavy CSV - rewards exactly the kind of automated, evidence-driven validation Sware is built to deliver.
Sware has raised roughly $26 million to date. Its June 2024 Series B was led by First Analysis, joining a syndicate that includes Insight Partners, LRVHealth and New Stack Ventures. As part of the round, First Analysis managing director Matt Nicklin joined the board.
We're investing in Sware because its proven technology can help companies escape growing challenges of validation debt and empower faster, more efficient, safer innovation.Matt Nicklin, Managing Director, First Analysis
The company launches as BTR, a regulatory technology firm serving healthcare, life sciences and SaMD.
BTR builds out its cloud-based computer system validation platform with an open API architecture.
BTR becomes Sware, with a new name and logo - a company life sciences innovators "can swear by."
Sware raises a $6M Series B led by First Analysis, adds AI assistance to Res_Q and earns SOC 2 Type II certification.
Selected to validate Salesforce Life Sciences Cloud, wins Box's Partner of the Year, and launches an enhanced AI-powered Res_Q plus GxPNext.
Automating these processes is the only way to eliminate this validation debt.Ellen Reilly, CEO, Sware
Its proven technology can help companies escape growing challenges of validation debt and empower faster, more efficient, safer innovation.Matt Nicklin, Managing Director, First Analysis
What sets Sware apart is their deep domain understanding and expertise of relevant requirements and technology.Alvin Coleman, VP IT, G1 Therapeutics
The name. "Sware" plays on a company you can swear by - trust being the whole promise in regulated software.
Res_Q. The flagship reads as "rescue" - aimed at validation teams drowning in paperwork.
The Salesforce tell. A platform giant chose Sware to validate its own Life Sciences Cloud rather than build the GxP piece in-house.
Real data, not web data. The Res_Q Data Cloud is trained on roughly a decade of actual regulated validation work.
Sware automates GxP validation - the FDA-mandated computer system validation that life sciences companies must perform on their software and equipment - through its cloud-native, AI-powered Res_Q platform and GxPNext developer product.
Res_Q is Sware's flagship SaaS platform. It lets pharmaceutical, biotech and medical device companies automate, integrate and scale validation across IT, manufacturing and lab systems in a single system, covering GCP, GLP, GMP and AI validation.
Yes. Sware was founded in 2015 as Boston Technology Research (BTR) and rebranded to Sware in 2022.
Sware has raised roughly $26M to date, including a $6M Series B in June 2024 led by First Analysis, with investors such as Insight Partners, LRVHealth and New Stack Ventures.
In 2025 Salesforce selected Sware to deliver AI-driven GxP computer system validation for its Life Sciences Cloud, helping customers deploy it as a validated solution faster.
Sources: Sware.com, BusinessWire, FinSMEs, Vator, Medical Device Network, LRVHealth, PitchBook, Tracxn, Axendia, HIT Consultant. Figures such as revenue and total funding are approximate, drawn from public sources.